Caxton Associates LLP Takes Position in MoonLake Immunotherapeutics $MLTX

Key Points

• Caxton Associates LLP purchased a new stake of 8,880 shares in MoonLake Immunotherapeutics, valued at approximately $347,000, in the first quarter.
• The company's shares are currently valued at $52.62, with a market capitalization of $3.38 billion and a price-to-earnings ratio of -18.93.
• Analysts have set an average target price of $74.43 for MoonLake Immunotherapeutics, indicating a consensus rating of "Moderate Buy".

Caxton Associates LLP bought a new stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,880 shares of the company's stock, valued at approximately $347,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MLTX. Nuveen LLC acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth approximately $26,308,000. Millennium Management LLC boosted its position in shares of MoonLake Immunotherapeutics by 3,343.2% during the first quarter. Millennium Management LLC now owns 344,320 shares of the company's stock worth $13,453,000 after buying an additional 334,320 shares during the period. Vestal Point Capital LP acquired a new position in shares of MoonLake Immunotherapeutics during the first quarter worth approximately $7,814,000. Westfield Capital Management Co. LP boosted its position in shares of MoonLake Immunotherapeutics by 9.4% during the first quarter. Westfield Capital Management Co. LP now owns 1,434,770 shares of the company's stock worth $56,056,000 after buying an additional 123,151 shares during the period. Finally, Point72 Asset Management L.P. acquired a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth approximately $5,346,000. 93.85% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MLTX has been the subject of several analyst reports. The Goldman Sachs Group boosted their price objective on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Rothschild & Co Redburn began coverage on MoonLake Immunotherapeutics in a research report on Monday, July 28th. They set a "neutral" rating and a $65.00 price objective for the company. Royal Bank Of Canada restated an "outperform" rating and issued a $67.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Finally, Redburn Atlantic upgraded MoonLake Immunotherapeutics to a "hold" rating in a research report on Monday, July 28th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $74.43.

MoonLake Immunotherapeutics Price Performance

Shares of NASDAQ:MLTX traded up $2.98 on Thursday, reaching $54.16. 725,428 shares of the company traded hands, compared to its average volume of 727,151. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $61.87. The company's 50 day moving average is $54.19 and its 200-day moving average is $45.44. The stock has a market capitalization of $3.48 billion, a PE ratio of -19.48 and a beta of 1.27. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 16.65.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same quarter in the prior year, the business posted ($0.39) earnings per share. As a group, analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.